 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Sacituzumab govitecan in endocrine-resistant HR+/HER2– advanced breast cancer

J Clin Oncol: Sacituzumab govitecan in endocrine-resistant HR+/HER2– advanced breast cancer

 Last Update: 2022-09-06
 Source: Internet
 Author: User

Tags

total source fitness

what 2 3 6

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The prognosis of patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) endocrine-resistant metastatic breast cancer treated with sequential single-agent chemotherapy is poor

This study is a global, randomized Phase 3 study to compare SG with clinician's choice of chemotherapy (Eribulin, vinorelbine, capecitabine, or gemcitabine) in endocrine-resistant HR+/HER2- locally recurrent disease Efficacy in patients with inoperable or metastatic breast cancer

A total of 543 patients were recruited, randomized to SG (n=272) or chemotherapy (n=271), median age was 56 years, 95% of patients had visceral metastases, and 99% had previously treated cells Cyclin-dependent kinase 4/6 inhibitor

Grade 3 or higher treatment-related adverse events (SG vs chemotherapy) were neutropenia (51% vs 38%) and diarrhea (9% vs 1%)

Compared with chemotherapy, SG demonstrated a significant PFS benefit with a manageable safety profile in patients with previously multi-treated, endocrine-resistant HR+/HER2- advanced breast cancer

Original source:

Rugo Hope S,Bardia Aditya,Marmé Frederik et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.